InnoCare Pharma Swings to Profit as H1 2026 Revenue Jumps 55.5% on Orelabrutinib Growth
InnoCare Pharma Limited (HKG: 9969; SHA: 688428) reported interim results for the first half of...
PIC
Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Simcere Pharmaceutical (HKG: 2096) released its interim results for the first half of 2026, reporting...
Henlius H1 2026 Earnings: Trastuzumab Sales Surge 27.3% Revenue Growth as Overseas Profit Quadruples
Shanghai Henlius Biotech, Inc. (HKG: 2696) released its first-half 2026 results, reporting total revenue of...
Ultomiris Wins NMPA Approval for PNH in China, Bringing Long‑Acting Ravulizumab C5 Inhibitor to Adult and Pediatric Patients
Ultomiris (ravulizumab injection), a long‑acting C5 complement inhibitor under AstraZeneca’s (NYSE: AZN) Rare Disease business,...
Pharmaron Posts 17.9% First‑Half Revenue Growth as CRO Demand Rebounds; CDMO and All Core Segments Expand
Pharmaron Beijing Co., Ltd. (HKG: 3759), a leading integrated CRO and CDMO service provider, announced...
Hengrui Wins NMPA Approval for HRS‑5965 – Complement Factor B Inhibitor for Complement Inhibitor‑Naive PNH Patients
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that China’s National Medical Products...
CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
CARsgen Therapeutics (HKG: 2171) reported interim results for the first half of 2026, highlighted by...
Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth
Ascentage Pharma Group International (NASDAQ: AAPG; HKG: 6855) reported first‑half 2026 revenue of RMB 302...
Jiangsu Hengrui 1H 2026: Innovative Drug Sales Jump 16.4% to RMB 8.8 Billion, Offset Generic Drag as R&D Spending Climbs 19%
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) reported first‑half 2026 results showing total...
Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation
U.S. President Donald Trump has chosen White House policy advisor Heidi Overton to lead the...
European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced that the European Commission (EC)...
Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
Navi Therapeutics (Shanghai) Co., Ltd. announced the successful completion of two financing rounds — Angel...
Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform
Ledeinno Medical Valley announced the completion of its Series B+ and Series B++ funding rounds...
AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
AstraZeneca plc (NYSE: AZN) announced the official market launch in China of Tezspire (generic name:...
ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions
ACROBiosystems Co., Ltd. (SHE: 301080) and Bailinke Pharmaceutical Technology (Shanghai) Co., Ltd. have entered into...
IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies
IASO Biotherapeutics, a Chinese cell therapy innovator, announced today that it has completed its acquisition...
AstraZeneca and Daiichi Sankyo’s Enhertu Wins China Approval for First-Line HER2-Positive Metastatic Breast Cancer in Combination With Pertuzumab
AstraZeneca plc (NYSE: AZN) and Daiichi Sankyo (TYO: 4568) announced that a new indication for...
NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib
The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.‘s (a genetic cancer testing service...
Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million
Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of a Series...
MSD Signs Oncology Collaboration With InventisBio Through MCICC to Accelerate Small‑Molecule Clinical Development
Merck & Co., Inc. (MSD; NYSE: MRK) announced that it has signed a collaboration agreement...